Inhibikase Therapeutics (IKT) Price/OCF Ratio: History & Chart

Inhibikase Therapeutics, Inc.(IKT)

Biotechnology · Wilmington, DE

$1.98-0.02 (-1.00%)

Delayed quote: Oct 6, 2026, 11:05 AM EDT

About Inhibikase Therapeutics, Inc.

Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate designed for the treatment of pulmonary arterial hypertension (PAH) was designed to improve areas of the molecule that might play a role in the gastrointestinal side effects associated with imatinib, while maintaining systemic exposure and efficacy through oral administration. The company has completed non-human primate safety studies and a bioequivalence clinical study in healthy volunteers, establishing dose equivalence with imatinib. IKT-001 is currently being evaluated in a global, adaptive Phase 3 clinical trial (IMPROVE-PAH), with endpoints including pulmonary vascular resistance and 6-minute walk distance. Inhibikase Therapeutics, Inc. entered into a collaborative research and development agreement with Sphaera Pharma Pte. Ltd., which was subsequently assigned to Pivot Holding LLC, for prodrug technology development and maintains an exclusive license for IKT-001. The company was founded in 2008 and is headquartered in Wilmington, Delaware.

Wilmington, DE

35 employees

www.inhibikase.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Mark T. Iwicki

View full financials

NAME	MARKET CAP	PRICE/OCF RATIO	TTM	3Y	5Y
Inhibikase Therapeutics, Inc. (IKT)	$261.43M	N/A	N/A	N/A	N/A
Palisade Bio, Inc. (PALI)vs ›	$262.97M	N/A	N/A	N/A	N/A
AC Immune S.A. (ACIU)vs ›	$262.07M	N/A	5.20	5.41	5.41
EyePoint Pharmaceuticals, Inc. (EYPT)vs ›	$267.45M	N/A	134.67	134.67	134.67
Eupraxia Pharmaceuticals Inc. (EPRX)vs ›	$265.50M	N/A	N/A	N/A	N/A
OraSure Technologies, Inc. (OSUR)vs ›	$264.72M	N/A	64.10	34.63	150.74
Lexeo Therapeutics, Inc. Common Stock (LXEO)vs ›	$258.73M	N/A	N/A	N/A	N/A
Century Therapeutics, Inc. (IPSC)vs ›	$256.22M	N/A	30.64	30.64	30.64
Anika Therapeutics, Inc. (ANIK)vs ›	$256.14M	42.85	27.05	50.78	58.49
Fate Therapeutics, Inc. (FATE)vs ›	$275.66M	N/A	N/A	N/A	N/A

NAME

MARKET CAP

PRICE/OCF RATIO

TTM

Inhibikase Therapeutics, Inc. (IKT)

$261.43M

N/A

Palisade Bio, Inc. (PALI)vs ›

$262.97M

N/A

AC Immune S.A. (ACIU)vs ›

$262.07M

N/A

5.20

5.41

EyePoint Pharmaceuticals, Inc. (EYPT)vs ›

$267.45M

N/A

134.67

Eupraxia Pharmaceuticals Inc. (EPRX)vs ›

$265.50M

N/A

OraSure Technologies, Inc. (OSUR)vs ›

$264.72M

N/A

64.10

34.63

150.74

Lexeo Therapeutics, Inc. Common Stock (LXEO)vs ›

$258.73M

N/A

Century Therapeutics, Inc. (IPSC)vs ›

$256.22M

N/A

30.64

Anika Therapeutics, Inc. (ANIK)vs ›

$256.14M

42.85

27.05

50.78

58.49

Fate Therapeutics, Inc. (FATE)vs ›

$275.66M

N/A

Price/OCF Ratio Formula & Definition

P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.

Price/OCF Ratio: N/A

IKT Price/OCF Ratio Metrics

IKT Competitors' Price/OCF Ratio

Operating Cash Flow Valuation

Price/OCF Ratio Formula & Definition

Related Metrics